Mankind Pharma (BOM:543904) Debt-to-Asset : 0.02 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma Debt-to-Asset?

Mankind Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹1,746 Mil. Mankind Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹326 Mil. Mankind Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₹119,633 Mil. Mankind Pharma's debt to asset for the quarter that ended in Mar. 2024 was 0.02.

Mankind Pharma Debt-to-Asset Historical Data

The historical data trend for Mankind Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma Debt-to-Asset Chart

Mankind Pharma Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

0.03

0.04

0.10

0.02

Mankind Pharma Quarterly Data
	Mar20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial							-	-	0.02	-	0.02

Competitive Comparison of Mankind Pharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mankind Pharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's Debt-to-Asset falls into.

Mankind Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Mankind Pharma's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1745.909	+	325.815)	/	119632.547
	=	0.02

Mankind Pharma's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1745.909	+	325.815)	/	119632.547
	=	0.02

Mankind Pharma (BOM:543904) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Mankind Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mankind Pharma (BOM:543904) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » Debt-to-Asset

Traded in Other Exchanges

MANKIND:India

Address

262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020

Website

https://www.mankindpharma.com

Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines